-
Je něco špatně v tomto záznamu ?
Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme
Z. Novy, J. Stepankova, M. Hola, D. Flasarova, M. Popper, M. Petrik,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
LO1304
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2009-03-01
Health & Medicine (ProQuest)
od 1997-01-01
- MeSH
- glioblastom diagnostické zobrazování metabolismus MeSH
- lidé MeSH
- myši SCID MeSH
- nádorové buněčné linie MeSH
- nádory mozku diagnostické zobrazování metabolismus MeSH
- oligopeptidy chemie MeSH
- PET/CT MeSH
- počítačová rentgenová tomografie MeSH
- pozitronová emisní tomografie metody MeSH
- radiofarmaka chemie MeSH
- radioizotopy fluoru MeSH
- radioizotopy galia chemie MeSH
- tkáňová distribuce MeSH
- transplantace nádorů MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
In this study, we have compared four 68Ga-labeled peptides (three Arg-Gly-Asp (RGD) peptides and substance-P) with two 18F-tracers clinically approved for tumor imaging. We have studied in vitro and in vivo characteristics of selected radiolabeled tracers in a glioblastoma multiforme tumor model. The in vitro part of the study was mainly focused on the evaluation of radiotracers stability under various conditions. We have also determined in vivo stability of studied 68Ga-radiotracers by analysis of murine urine collected at various time points after injection. The in vivo behavior of tested 68Ga-peptides was evaluated through ex vivo biodistribution studies and PET/CT imaging. The obtained data were compared with clinically used 18F-tracers. 68Ga-RGD peptides showed better imaging properties compared to 18F-tracers, i.e., higher tumor/background ratios and no accumulation in non-target organs except for excretory organs.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034458
- 003
- CZ-PrNML
- 005
- 20191008104725.0
- 007
- ta
- 008
- 191007s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules24132496 $2 doi
- 035 __
- $a (PubMed)31288488
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Novy, Zbynek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic. novy.zbynek@gmail.com.
- 245 10
- $a Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme / $c Z. Novy, J. Stepankova, M. Hola, D. Flasarova, M. Popper, M. Petrik,
- 520 9_
- $a In this study, we have compared four 68Ga-labeled peptides (three Arg-Gly-Asp (RGD) peptides and substance-P) with two 18F-tracers clinically approved for tumor imaging. We have studied in vitro and in vivo characteristics of selected radiolabeled tracers in a glioblastoma multiforme tumor model. The in vitro part of the study was mainly focused on the evaluation of radiotracers stability under various conditions. We have also determined in vivo stability of studied 68Ga-radiotracers by analysis of murine urine collected at various time points after injection. The in vivo behavior of tested 68Ga-peptides was evaluated through ex vivo biodistribution studies and PET/CT imaging. The obtained data were compared with clinically used 18F-tracers. 68Ga-RGD peptides showed better imaging properties compared to 18F-tracers, i.e., higher tumor/background ratios and no accumulation in non-target organs except for excretory organs.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádory mozku $x diagnostické zobrazování $x metabolismus $7 D001932
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a radioizotopy fluoru $7 D005462
- 650 _2
- $a radioizotopy galia $x chemie $7 D005710
- 650 _2
- $a glioblastom $x diagnostické zobrazování $x metabolismus $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a myši SCID $7 D016513
- 650 _2
- $a transplantace nádorů $7 D009368
- 650 _2
- $a oligopeptidy $x chemie $7 D009842
- 650 _2
- $a PET/CT $7 D000072078
- 650 _2
- $a pozitronová emisní tomografie $x metody $7 D049268
- 650 _2
- $a radiofarmaka $x chemie $7 D019275
- 650 _2
- $a tkáňová distribuce $7 D014018
- 650 _2
- $a počítačová rentgenová tomografie $7 D014057
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Stepankova, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic.
- 700 1_
- $a Hola, Michaela $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic.
- 700 1_
- $a Flasarova, Dominika $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic.
- 700 1_
- $a Popper, Miroslav $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic.
- 700 1_
- $a Petrik, Milos $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic. milos.petrik@upol.cz.
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 24, č. 13 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31288488 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191008105142 $b ABA008
- 999 __
- $a ok $b bmc $g 1451118 $s 1073008
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c 13 $e 20190708 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a LO1304 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20191007
